ストックスクリーナーアプリを入手
1.79
1.70%
0.03
前日終値:
$1.76
開ける：
$1.75
24時間の取引高:
14,794
Relative Volume:
0.06
時価総額：
$31.67B
収益：
$35.75M
当期純損益:
$11.57M
株価収益率:
-0.4702
EPS:
-3.8069
ネットキャッシュフロー:
$-26.25M
1週間 パフォーマンス:
-2.72%
1か月 パフォーマンス:
-19.73%
6か月 パフォーマンス:
-78.94%
1年 パフォーマンス:
-84.38%
1日の値動き範囲:
$1.73
$1.7957
1週間の範囲:
$1.73
$1.85
52週間の値動き範囲:
$1.71
$20.28
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
RDHL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-08-31 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-11 | 開始されました | BTIG Research | Buy |
| 2019-07-12 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | 開始されました | Nomura | Buy |
| 2017-10-06 | 開始されました | Seaport Global Securities | Buy |
| 2017-10-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-24 | 繰り返されました | FBR & Co. | Outperform |
| 2016-07-27 | 繰り返されました | FBR Capital | Outperform |
| 2015-09-29 | 開始されました | Nomura | Buy |
| 2015-07-29 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-15 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Redhill Biopharma Ltd Adr (RDHL) 最新ニュース
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
RDHL Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Cathie Wood Predictions 2022 - New Trader U
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib - Yahoo Finance
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma Ltd Adr (RDHL) 財務データ
収益
当期純利益
現金流量
EPS
1.55%
4.28%
大文字化:
|
ボリューム (24 時間):